论文部分内容阅读
目的 :探讨sP -selectin与原发性肝癌发展及转移的关系以及化疗对原发性肝癌患者血浆中sP -se lectin水平的影响。方法 :用ELISA法检测54例中晚期原发性肝癌患者化疗前后血浆sP -selectin的含量。结果 :中晚期原发性肝癌患者化疗前后血浆中可溶性P -selectin均明显高于正常对照组(P<0 01) ;而且与原发性肝癌的临床分期及治疗效果有关 ,Ⅲ期患者较Ⅱ期患者高(P<0 05) ,治疗前较治疗后高(P<0 05)。结论 :中晚期原发性肝癌患者血浆可溶性P -selectin含量比正常人高 ,而且随着病情的发展及疗效而改变 ,故检测sP -selectin有可能成为原发性肝癌辅助诊断、病情发展及疗效观察的一项有价值的指标
Objective: To investigate the relationship between sP-selectin and the development and metastasis of primary liver cancer, and the effect of chemotherapy on plasma sP-se lectin levels in patients with primary liver cancer. METHODS: Plasma sP-selectin levels in 54 patients with advanced primary liver cancer before and after chemotherapy were detected by ELISA. Results: Plasma soluble P-selectin levels in patients with advanced primary liver cancer before and after chemotherapy were significantly higher than those in the normal control group (P<0 01), and were related to clinical staging and treatment efficacy of primary liver cancer. The patient’s age was high (P < 0 05), and it was higher before treatment than after treatment (P <0 05). Conclusions: Plasma soluble P-selectin levels in patients with advanced primary liver cancer are higher than those in normal subjects, and change with the development of the disease and its efficacy. Therefore, detection of sP-selectin may become a primary diagnosis, progression and efficacy of primary liver cancer. A valuable indicator of observation